]>
IRCT2017062434726N1 IRCT 2017-08-31 Vice chancellor for research, Esfahan University of Medical Sciences Effect of BMP2 versus MTA as a medicament in pulpotomy of primary molars - A comparative study of clinical and radiographic success rates of BMP2 and MTA in pulpotomy of primary molars in 3 to 6 year old children 2017-05-22 anticipated 50 Complete https://irct.ir/trial/26464 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: The Split mouth design is applied in this study. Base on block randomization table all of the participants will be assigned to receive pulpotomy therapy with MTA in primary mandibular molars of one side and pulpotomy with BMP2 in primary mandibular molars of another side. 3 reversible pulpitis. Intervention 1: Intervention group: َAfter pulpotomy treatment, 1 microgram recombinant human bone morphogenetic protein 2 (rhBMP2) is placed in pulp chamber. Intervention 2: group2: After pulpotomy treatment, MTA paste is placed in pulp chamber as a standard pulpotomy medicament.
public Dr Sanaz Ziaei
Pediatric Department, Dental school, Esfahan University of Medical Sciences, Hezarjerib street
Esfahan Iran (Islamic Republic of) +98 31 3792 5591 sanaz20_2005@yahoo.com Esfahan University of Medical Sciences scientific Dr Sanaz Ziaei
Pediatric Department, Dental school, Esfahan University of Medical Sciences, Hezarjerib street
Esfahan Iran (Islamic Republic of) +98 31 3792 5591 sanaz20_2005@yahoo.com Esfahan University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: Exposed vital tooth without signs and symptoms; Teeth with no clinical or radiographic evidence of pulp degeneration; The possibility of proper restoration of the tooth. Exclusion criteria: Teeth with signs and symptoms; Clinical or radiographic evidence of pulp degeneration; physiologic mobility; Evidence of any pathologial root resorption. 3 years 6 years Both k04.0 reversible pulpitis Treatment - Other Treatment - Other Intervention group: َAfter pulpotomy treatment, 1 microgram recombinant human bone morphogenetic protein 2 (rhBMP2) is placed in pulp chamber. group2: After pulpotomy treatment, MTA paste is placed in pulp chamber as a standard pulpotomy medicament. Pain. Timepoint: before intervention, 3 months, 6months, 9months and 12 months after intervention. Method of measurement: clinical examination. Sensitive to percussion. Timepoint: before intervention, 3 months, 6months, 9months and 12 months after intervention. Method of measurement: clinical examination. Swelling. Timepoint: before intervention, 3 months, 6months, 9months and 12 months after intervention. Method of measurement: clinical examination. Sinus tract. Timepoint: before intervention, 3 months, 6months, 9months and 12 months after intervention. Method of measurement: clinical examination. Pathologic mobility. Timepoint: before intervention, 3 months, 6months, 9months and 12 months after intervention. Method of measurement: clinical examination. Internal resorption. Timepoint: before intervention, 3months, 6months, 9months and 12months after intervention. Method of measurement: radigraphic examination. External resorption. Timepoint: before intervention, 3months, 6months, 9months and 12months after intervention. Method of measurement: radigraphic examination. PDL widening. Timepoint: before intervention, 3months, 6months, 9months and 12months after intervention. Method of measurement: radigraphic examination. Radiolucency. Timepoint: before intervention, 3months, 6months, 9months and 12months after intervention. Method of measurement: radigraphic examination. Kowsar Kohan Gen company Vice chancellor for research, Esfahan University of Medical Sciences Kowsar Kohan Gen company Approved 2016-05-27 Ethics committe of Esfahan University of Medical Sciences Ethics committe, Dental school, Esfahan University of Medical Sciences, Hezarjerib street, Esfahan Esfahan Iran (Islamic Republic of)